Caricamento in corso... Attendere.
Profilo società
ABIONYX Pharma SA is specialized in research & development into HDL therapies (High Density lipoproteins) intended for the treatment of cardiovascular and metabolic disorders. HDLs, also known as good cholesterol, are fat and protein complexes that contribute to the transportation of cholesterol from the body's tissues to the liver and are linked to a decrease in the risk of atherosclerosis and coronary diseases.
At the end of 2024, the company boasted a portfolio of 3 products in clinical development.
Fonte:
Cofisem
-
Ultimo aggiornamento:
19 Mar 2025
Dirigenti principali
| Chief Executive Officer | Cyrille Tupin | ||||
| Chief Financial Officer | Emmanuel de Fougeroux | ||||
| VP, Financial Communication | Emmanuel de Fougeroux | ||||
| Chief Operating Officer | Constance Keyserling | ||||
| Director Research & Development | Rob Scott | ||||
| Head of Investor Relations | Louis-Victor Delouvrier | ||||
| Fonte: Cofisem - Ultimo aggiornamento: 19 Mar 2025 | |||||
Dati principali
| Millenium | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Net sales | 4.551 | 4.640 | 5.252 | 675 | 0 |
| Income from ordinary activities | 4.551 | 4.640 | 5.252 | 675 | 0 |
| Operating income | -4.465 | -3.412 | -4.109 | -5.952 | -2.968 |
| Cost of financial indebtedness net | -67 | -41 | 55 | 4 | -55 |
| Equity-accounted companies contribution to income | |||||
| Net profit from discontinued activities | |||||
| Net income | -4.381 | -3.518 | -4.206 | -5.822 | -1.886 |
| Net income (Group share) | -4.381 | -3.518 | -4.206 | -5.822 | -1.886 |
| Fiscal year end | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
| Length of fiscal year (month) | 12 | 12 | 12 | 12 | 12 |
| Currency & Unit | EUR - thousands | EUR - thousands | EUR - thousands | EUR - thousands | EUR - thousands |
| Account Standards | IFRS | IFRS | IFRS | IFRS | IFRS |
| Fonte: Cofisem - Ultimo aggiornamento: 19 Mar 2025 | |||||
Informazioni sull’azionariato
Indirizzo
ABIONYX Pharma SA
Bât. D2 33-43 Avenue Georges Pompidou
FR-31130
Balma
France
Telefono:
+33 (0)5 62 24 97 06
Fax:
+33 (0)5 61 57 34 12
Fonte:
Cofisem
-
Ultimo aggiornamento:
19 Mar 2025